FDA Approves AstraZeneca and Merck's Lynparza for Pancreatic Cancer

AstraZeneca and Merck are closing out 2019 on a high note with another approval for its PARP inhibitor Lynparza. This morning the U.S. Food and Drug Administration (FDA) green lit the drug as a maintenance treatment for pancreatic cancer patients.